Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001415889-25-009648
Filing Date
2025-04-02
Accepted
2025-04-02 16:20:54
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 13729
2 JOINT FILING AGREEMENT ex-99-04022025_080452.htm EX-99.1 2700
  Complete submission text file 0001415889-25-009648.txt   18273
Mailing Address 171 OYSTER POINT BLVD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-475-2820
Surrozen, Inc./DE (Subject) CIK: 0001824893 (see all company filings)

EIN.: 301374889 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91867 | Film No.: 25804927
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 4 EMBARCADERO CENTER, SUITE 3110 SAN FRANCISCO CA 94111
Business Address 4 EMBARCADERO CENTER, SUITE 3110 SAN FRANCISCO CA 94111 (415) 993-8565
5AM Partners VII, LLC (Filed by) CIK: 0001873545 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G